Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas

Leukemia. 2022 Feb;36(2):588-590. doi: 10.1038/s41375-021-01418-8. Epub 2021 Sep 20.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal* / therapeutic use
  • Antigens, CD20* / immunology
  • BNT162 Vaccine* / administration & dosage
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphoma, B-Cell* / blood
  • Lymphoma, B-Cell* / drug therapy
  • Lymphoma, B-Cell* / virology
  • Lymphoma, Non-Hodgkin* / blood
  • Lymphoma, Non-Hodgkin* / drug therapy
  • Lymphoma, Non-Hodgkin* / virology
  • Male
  • Prognosis

Substances

  • Antibodies, Monoclonal
  • Antigens, CD20
  • BNT162 Vaccine